Skip to main content
OpenTrials
Completed

NCT Number: NCT05142059

Fall Risk Assessment in a Population of Charcot-Marie-Tooth Disease Type 1A (CMT 1A) by Timed Up and Go Test

The main objective of this study is to explore the relationship between the onset of fall and the time taken to complete the Timed Up and Go test (TUG) in this CMT1A patient population.

The investigators hypothesize that patients with balance disorders and therefore a risk of major fall will require a longer time to perform the Timed Up and Go test. In addition, it seems important to confirm that the severity of the disease has a negative impact on the frequency of balance disorders.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Charcot-Marie-Tooth Type 1A Neuropathy Charcot-Marie-Tooth Disease Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hereditary Sensory and Motor Neuropathy Heredodegenerative Disorders, Nervous System Nervous System Diseases Nervous System Malformations Neurodegenerative Diseases Neuromuscular Diseases Peripheral Nervous System Diseases Polyneuropathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Clermont-Ferrand

Clermont-Ferrand, 63000, France

About this study

Charcot-Marie Tooth disease is the most frequent and common inherited neuropathy with the various forms and subtypes. The CMT-1A is the most frequent form of the disease and represents more than eighty percent of the all subtypes. In view of different clinical elements (muscular strength deficit, walking and balance disorders, podological impairment), patients with CMT seem to be able to present an increased risk of fall. In 2017 pilot study supports this. More recently, a study by Ramdharry et al. appears to confirm this with a cohort of 252 patients with CMT, 86% of whom have experienced at least one major fall or loss of balance. This increased incidence of falls is also found in children and adolescents with CMT with consequences in terms of injury and management.

Systematic screening of the risk of falls in this population is necessary, but no prospective studies on the occurrence of falls and its detection have yet been carried out in this population.

A study focusing on this issue in order to standardize the assessment of postural control disorders using a simple test of common clinical practice seems necessary.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients older than 18 years
  • Diagnosis of Charcot Marie Tooth disease, type 1A confirmed by molecular biology (duplication 17.p11.2) and by a pathological electromyogram, that is to say with demyelinating impairment (+/- axonal) dependent length
  • Listening and written French
  • Strength of the quadriceps superior to 2/5 MMT MRC
  • Agreement after written information, clear and honest about the purpose of the study, the nature of the tests and their possible side effects or bothersome
  • Health insurance cover

Exclusion criteria

  • Presence of other neurological comorbidity
  • Presence of coronary artery disease unstabilized
  • Peripheral neuropathy of other causes: diabetes, monoclonal gammopathy, malignancy, solid cancer, systemic autoimmune disease (lupus, Sjögren's disease, Wegener sarcoidosis ...), infectious disease (viral hepatitis, HIV ...), drugs known to be responsible for iatrogenic neuropathy.
  • Gait trouble of other origin
  • Patients unable to give their consent.
  • Intellectual deficit that does not allow to comply with tests
  • Patient under guardianship, or protection of justice.

Treatment and study plan

Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A

Diagnostic Test

The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.

Primary outcomes

  1. Main explanatory variable: Time to complete the Timed Up and Go test (TUG) (in seconds)

    Time frame: 1 day , 6 months, 12 months

    It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. Investigators measures an evolution or not at 6 months and 1 years.

  2. Main dependent variable: Self-reported occurrence of fall.

    Time frame: 6 months , 12 months

    A fall book will be issued to the patient during the first consultation to trace the date, the circumstances of occurrence. Investigators seek to find an improvement or not in the number of falls at 6 months and 1 year.

Secondary outcomes

  1. : Muscle Strength measured by Medical Research Council (MRC) Scale

    Time frame: Day 0 , 12 months

    The muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle. The patient's effort is graded on a scale of 0-5: Grade 5: Muscle contracts normally against full resistance and Grade 0: No movement is observed.

  2. Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s (eccentric contraction) (Nm).

    Time frame: Day 0 , 12 months

    Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s will be measured with the device.

  3. Maximum voluntary isometric strength of the quadriceps muscles at 45° (Nm).

    Time frame: Day 0 , 12 months

    Maximum voluntary isometric strength of the quadriceps muscles will be measured with the CYBEX device.

  4. Body Mass Index (Kg/m²).

    Time frame: Day 0 , 12 months

    BMI will be calculated (weight in kilograms divided by height in meters squared).

  5. Height (cm).

    Time frame: Day 0 , 12 months

    Height will be measured with a wall mounted tape measure and according to the ISAK recommendations.

  6. Weight (Kg).

    Time frame: Day 0 , 12 months

    Weight will be measured with the medical body weight scale SECA® and according to the ISAK recommendations.

  7. Sarcopenia risk.

    Time frame: : Day 0 , 12 months

    Sarcopenia risk will be evaluated with the SARC-F Questionnaire.

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Acronym: DeteCTCMT

Important dates

Study start
2020
Primary completion
2023
Study completion
2024
First posted
Dec 2, 2021
Registry last updated
Dec 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.